Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Authors

Tait D Shanafelt, Stanford University
Amanda F Cashen, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

1-14-2025

Volume

9

Issue

1

First Page

224

Last Page

228

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2024013474

Rights and Permissions

Shanafelt TD, Wang XV, Hanson CA, Paietta E, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912. Blood Adv. 2025 Jan 14;9(1):224-228. doi: 10.1182/bloodadvances.2024013474. © 2025 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Shanafelt, Tait D; Cashen, Amanda F; and et al., "Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912." Blood Advances. 9, 1. 224 - 228. (2025).
https://digitalcommons.wustl.edu/oa_4/4805

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.